Comparison of Gefitinib versus Docetaxel in Patients with Pre-Treated Non-Small Cell Lung Cancer (NSCLC).
- Author:
Vera HIRSH
1
Author Information
- Publication Type:Meta-Analysis ; Review
- Keywords: Gefitinib; Docetaxel; 2nd line treatment; 3rd line treatment; Non-small cell lung carcinoma; Metastatic
- MeSH: Administration, Oral; Asian Continental Ancestry Group; Carcinoma, Non-Small-Cell Lung; Humans; Oligosaccharides; Protein-Tyrosine Kinases; Quality of Life; Quinazolines; Receptor, Epidermal Growth Factor; Taxoids
- From:Journal of Lung Cancer 2009;8(2):61-66
- CountryRepublic of Korea
- Language:English
- Abstract: More effective treatments in first, second, and third-line of metastatic non-small cell lung cancer (NSCLC) enable patients to live longer, with a better quality of life (QOL). Especially epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) contributed to this improvement. Gefitinib was compared with Docetaxel in four randomized trials, i.e., SIGN, Japanese V-1532, Korean ISTANA, and INTEREST in second or third-line treatment of metastatic NSCLC. In all the trials, and also by meta-analysis of 2,257 patients in these trials, Gefitinib was found non-inferior or superior to Docetaxel, with less toxicity, convenient oral administration, and better QOL. Detailed results are presented in the review article. Knowing that every line of treatment we may lose about 50% of patients for further treatment, it is very important to offer each patient the best option for every line of treatment. Gefitinib has a favorable benefit-risk profile compared with Docetaxel in this patient population.
